

Haematologica
HAEMATOL/2020/274753
Version 1

BETing on rational combination therapy in mutant FLT3 AML

Richard M. Stone

Disclosures: Work under consideration: no conflicts Outside the submitted work, past 36 months: Ad hoc ad boards/consulting: Hoffman-LaRoche, Pfizer, Otsuka, Novartis, Jazz, Celgene (also DSMB), Astellas, Arog, Amgen, Agios(also clinical research to my instituton for protocol on which I am PI), Actinum, Abbvie (also clinical research to my instituton for protocol on which I am PI), Takeda (also DSMB), Macrogneics, Janssen, Gemoab, Daichii-Sanko, Biolinerx, Trovagene, Stemline, AStraZeneca, Elevate Bio, BerGenBio, Foghorn, Innate Pharma. GSK, Syndax (also clinical research to my instituton for protocol on which I am PI), Syros DSMB: Argenix, Syntrix Clinical research to my instituton for protocol on which I am PI: Lilly Patents or Copyrights; none